Noven Drug Patent Portfolio
Noven owns 4 orange book drugs protected by 19 US patents Given below is the list of Noven's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11559501 | Transdermal amphetamine compositions with low levels of carbamate | 06 Jan, 2042 | Active |
| US9456993 | Compositions and methods for transdermal delivery of amphetamine | 24 Oct, 2033 | Active |
| US9474722 | Compositions and methods for transdermal delivery of amphetamine | 24 Oct, 2033 | Active |
| US8231906 | Transdermal estrogen device and delivery | 04 Jul, 2030 | Active |
| US9724310 | Transdermal estrogen device and delivery | 10 Jul, 2028 | Active |
| US9730900 | Transdermal estrogen device and delivery | 10 Jul, 2028 | Active |
| US9833419 | Transdermal estrogen device and delivery | 10 Jul, 2028 | Active |
| US8632802 | Device for transdermal administration of drugs including acrylic polymers | 07 Oct, 2025 | Expired |
| US9034370 | Device for transdermal administration of drugs including acrylic polymers | 07 Oct, 2025 | Expired |
| US9668981 | Device for transdermal administration of drugs including acrylic based polymers | 07 Oct, 2025 | Expired |
| US8591941 | Transdermal drug delivery device including an occlusive backing | 07 Oct, 2025 | Expired |
| US6841716 | Patch | 27 Apr, 2020 | Expired |
| US6210705 | Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate | 30 Sep, 2018 | Expired |
| US6348211 | Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate | 30 Sep, 2018 | Expired |
| US5656286 | Solubility parameter based drug delivery system and method for altering drug saturation concentration | 12 Aug, 2014 | Expired |
| US5646286 | Palladium catalyzed vinylic substitution reactions with 2-substituted-pyridines | 12 Aug, 2014 | Expired |
| US6024976 | Solubility parameter based drug delivery system and method for altering drug saturation concentration | 07 Jan, 2014 | Expired |
| US5474783 | Solubility parameter based drug delivery system and method for altering drug saturation concentration | 12 Dec, 2012 | Expired |
| US5958446 | Solubility parameter based drug delivery system and method for altering drug saturation concentration | 12 Dec, 2012 | Expired |
Latest Legal Activities on Noven's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Noven.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 17 Jan, 2024 | US8231906 |
|
Recordation of Patent Grant Mailed
Critical
| 24 Jan, 2023 | US11559501 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 24 Jan, 2023 | US11559501 |
|
Email Notification
Critical
| 05 Jan, 2023 | US11559501 |
|
Issue Notification Mailed
Critical
| 04 Jan, 2023 | US11559501 |
| Dispatch to FDC | 23 Dec, 2022 | US11559501 |
|
Application Is Considered Ready for Issue
Critical
| 23 Dec, 2022 | US11559501 |
| Response to Reasons for Allowance | 16 Dec, 2022 | US11559501 |
|
Issue Fee Payment Verified
Critical
| 16 Dec, 2022 | US11559501 |
|
Issue Fee Payment Received
Critical
| 16 Dec, 2022 | US11559501 |
|
Electronic Review
Critical
| 22 Nov, 2022 | US11559501 |
|
Mail Notice of Allowance
Critical
| 22 Nov, 2022 | US11559501 |
|
Email Notification
Critical
| 22 Nov, 2022 | US11559501 |
|
Notice of Allowance Data Verification Completed
Critical
| 17 Nov, 2022 | US11559501 |
|
Information Disclosure Statement considered
Critical
| 07 Nov, 2022 | US11559501 |
Noven's Drug Patent Litigations
Noven's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Dec 04, 2017, against patent number US9730900. The petitioner Mylan Technologies, Inc., challenged the validity of this patent, with Noven Pharmaceuticals, Inc. as the respondent. Click below to track the latest information on how companies are challenging Noven's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US9833419 | May, 2018 |
Terminated-Settled
(10 Sep, 2018)
| Noven Pharmaceuticals, Inc. | Mylan Technologies, Inc. |
| US9724310 | December, 2017 |
Terminated-Settled
(12 Jun, 2018)
| Noven Pharmaceuticals, Inc. | Mylan Technologies, Inc. |
| US9730900 | December, 2017 |
Terminated-Settled
(12 Jun, 2018)
| Noven Pharmaceuticals, Inc. | Mylan Technologies, Inc. |
Noven Drug Patents' Oppositions Filed in EPO
Noven drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Mar 23, 2016, by 3M Innovative Properties Company. This opposition was filed on patent number EP09790211A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP09790211A | Mar, 2016 | 3M Innovative Properties Company | Revoked |
Noven's Family Patents
Recent FDA approvals and tentative approvals for Noven
This section lists recent FDA approvals and tentative approvals for Lupin, covering innovator and generic drugs with key regulatory details and timelines.
Generic drugs
Includes generic drug submissions with tentative FDA approvals, not yet marketable due to patent or exclusivity restrictions.
| Drug Name | Submission class (FDA) | Submission Category | Submission Date |
|---|---|---|---|
| Nitroglycerin |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 26 Nov, 1996 |
| Nitroglycerin |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 26 Nov, 1996 |
| Nitroglycerin |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 26 Nov, 1996 |
Noven Drug List
Given below is the complete list of Noven's drugs and the patents protecting them.
1. Combipatch
Combipatch is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5656286 | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
12 Aug, 2014
(11 years ago)
| Expired |
| US6024976 | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
07 Jan, 2014
(12 years ago)
| Expired |
| US5474783 | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
12 Dec, 2012
(13 years ago)
| Expired |
| US5958446 | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
12 Dec, 2012
(13 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Combipatch's drug page
2. Daytrana
Daytrana is protected by 6 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8632802 | Device for transdermal administration of drugs including acrylic polymers |
07 Oct, 2025
(3 months ago)
| Expired |
| US9034370 | Device for transdermal administration of drugs including acrylic polymers |
07 Oct, 2025
(3 months ago)
| Expired |
| US9668981 | Device for transdermal administration of drugs including acrylic based polymers |
07 Oct, 2025
(3 months ago)
| Expired |
| US6210705 | Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate |
30 Sep, 2018
(7 years ago)
| Expired |
| US6348211 | Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate |
30 Sep, 2018
(7 years ago)
| Expired |
| US5958446 | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
12 Dec, 2012
(13 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Daytrana's drug page
3. Minivelle
Minivelle is protected by 8 patents, out of which 4 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8231906 | Transdermal estrogen device and delivery |
04 Jul, 2030
(4 years from now)
| Active |
| US9724310 | Transdermal estrogen device and delivery |
10 Jul, 2028
(2 years from now)
| Active |
| US9730900 | Transdermal estrogen device and delivery |
10 Jul, 2028
(2 years from now)
| Active |
| US9833419 | Transdermal estrogen device and delivery |
10 Jul, 2028
(2 years from now)
| Active |
| US6841716 | Patch |
27 Apr, 2020
(5 years ago)
| Expired |
| US5646286 | Palladium catalyzed vinylic substitution reactions with 2-substituted-pyridines |
12 Aug, 2014
(11 years ago)
| Expired |
| US5656286 | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
12 Aug, 2014
(11 years ago)
| Expired |
| US6024976 | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
07 Jan, 2014
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Minivelle's drug page
4. Xelstrym
Xelstrym is protected by 6 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11559501 | Transdermal amphetamine compositions with low levels of carbamate |
06 Jan, 2042
(15 years from now)
| Active |
| US9456993 | Compositions and methods for transdermal delivery of amphetamine |
24 Oct, 2033
(7 years from now)
| Active |
| US9474722 | Compositions and methods for transdermal delivery of amphetamine |
24 Oct, 2033
(7 years from now)
| Active |
| US8591941 | Transdermal drug delivery device including an occlusive backing |
07 Oct, 2025
(3 months ago)
| Expired |
| US8632802 | Device for transdermal administration of drugs including acrylic polymers |
07 Oct, 2025
(3 months ago)
| Expired |
| US9034370 | Device for transdermal administration of drugs including acrylic polymers |
07 Oct, 2025
(3 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xelstrym's drug page